Chronic inflammatory bowel diseases (IBD) remain among the most challenging conditions in modern gastroenterology, characterized by their persistent nature, debilitating symptoms, and the long-term risk of severe complications, including colorectal cancer. For many patients, the diagnosis marks the beginning of a lifelong struggle with an overactive immune system that mistakenly attacks the gastrointestinal tract. However, a significant scientific breakthrough from researchers at Charité – Universitätsmedizin Berlin may offer a new path forward for those who have exhausted existing treatment options.
In a study recently published in the prestigious journal Nature Immunology, a team of scientists led by Professor Ahmed Hegazy has identified a specific interaction between two messenger substances in the immune system that serves as a primary driver of chronic intestinal inflammation. The discovery of this signaling pathway not only sheds light on why some patients fail to respond to traditional therapies but also highlights a promising new target for precision medicine.
The Heavy Burden of IBD on Young Adults
The impact of chronic inflammatory bowel diseases is often most profound due to the age at which they typically manifest. While these conditions can develop at any time, they most frequently emerge in young people between the ages of 15 and 29. This is a critical developmental window, encompassing the completion of higher education, the beginning of professional careers, and the formation of long-term personal relationships.
The two most common forms of the disease, Crohn’s disease and ulcerative colitis, present significant hurdles to a normal life. The onset can be insidious, with symptoms developing gradually, or it can arrive in sudden, violent flare-ups. Patients often report severe abdominal cramps, persistent diarrhea, significant weight loss, and profound fatigue. Beyond the physical toll, the emotional stress and social stigma associated with these symptoms can lead to isolation and mental health challenges.
While both conditions involve chronic inflammation, they affect the body differently. Ulcerative colitis is generally confined to the inner lining of the large intestine (colon) and rectum. In contrast, Crohn’s disease is more versatile and aggressive; it can affect any part of the digestive tract from the mouth to the anus, often involving the entire thickness of the intestinal wall. If left unchecked, this ongoing inflammation leads to lasting tissue damage, scarring (strictures), and an exponentially higher risk of developing bowel cancer over time.
The Limitations of Current Therapies
For decades, the primary goal of IBD treatment has been to achieve and maintain remission by suppressing the immune system. Historically, this involved broad-acting medications like corticosteroids or immunosuppressants that lowered the body’s overall immune response. While effective for some, these "blunt instrument" approaches often carry significant side effects and do not address the specific molecular drivers of the disease.
The advent of "biologics"—targeted therapies that block specific inflammatory proteins—marked a revolution in IBD care. These drugs interrupt the inflammatory process by neutralizing messenger substances such as tumor necrosis factor (TNF). However, the medical community has long faced a frustrating reality: a substantial portion of patients either do not respond to these modern treatments or lose responsiveness over time.
"At the clinic, we mainly see young patients who are just beginning their professional lives," says Professor Ahmed Hegazy, a researcher at Charité’s Department of Gastroenterology, Infectiology and Rheumatology. "So far, we have only been able to slow down the progression of the disease and alleviate symptoms. But not all patients respond well to existing treatments, so new therapeutic approaches are urgently needed."
Uncovering the Uncontrolled Chain Reaction
Professor Hegazy and his team spent five years investigating the intricate defense mechanisms of the immune system and how they go awry in the gut. Their research focused on a messenger molecule called oncostatin M (OSM). Produced by specific immune cells, OSM is an inflammation-promoting protein that had previously been noted for its presence in high concentrations within the inflamed tissue of IBD patients.
The Charité team sought to understand why OSM was so influential. Through the use of state-of-the-art single-cell sequencing, they were able to map the cellular landscape of the gut in unprecedented detail. They compared healthy tissue samples with those taken from patients at various stages of chronic intestinal disease. The results were striking: in inflamed tissue, an unexpected variety of cell types were found to have developed receptors, or binding sites, for oncostatin M. Simultaneously, an influx of immune cells began producing the protein in large quantities.
However, the most significant discovery involved the interaction between OSM and another protein, Interleukin-22 (IL-22). Under normal circumstances, IL-22 is a "guardian" of the gut. It supports the cells lining the intestine, helping to maintain the protective barrier that keeps bacteria and toxins from entering the bloodstream.
In the context of chronic inflammation, however, this protective mechanism is hijacked. The researchers found that IL-22 actually makes the gut lining more sensitive to the damaging effects of oncostatin M by increasing the number of OSM receptors.
"These two immune messengers work together and amplify the inflammation, drawing more immune cells into the intestine, like a fire that keeps getting more fuel and spreads," Professor Hegazy explains. This synergy creates a self-sustaining cycle of inflammation that the body cannot shut down on its own.
A Biomarker for Treatment Failure
The study’s findings also provide a potential explanation for why certain patients fail to respond to current standard-of-care treatments. The research team observed that patients with particularly high levels of oncostatin M were the most likely to experience treatment failure when using common biologics.
This suggests that OSM could serve as a vital biomarker. By measuring OSM levels in a patient’s tissue or blood, doctors might soon be able to predict whether a specific therapy will be effective before even starting it. This move toward personalized medicine would allow high-risk patients to bypass ineffective treatments and move directly to more aggressive or specialized interventions.
"It was especially interesting for us to see that patients with high levels of oncostatin M do not respond to several common therapies," says Hegazy. "This means that oncostatin M levels could help predict treatment failure and may serve as a biomarker for more severe disease. That’s exactly where we focused our efforts: we wanted to understand this signaling pathway better and find ways to block it with targeted treatments."
The Link to Colorectal Cancer
One of the most concerning aspects of long-term IBD is the development of colitis-associated colorectal cancer. The chronic cycle of tissue damage and rapid cell regeneration creates an environment where genetic mutations are more likely to occur.
When examining tissue samples from patients with colorectal cancer caused by IBD, the Charité researchers found a particularly high concentration of oncostatin M receptors in the areas immediately surrounding the tumors. Interestingly, these receptors were not present in the same density in healthy surrounding tissue. This observation strongly suggests that the OSM signaling pathway not only drives inflammation but may also play a direct role in promoting the development and growth of cancer cells.
In experimental models, the team was able to specifically block the binding sites for oncostatin M. The results were highly encouraging, showing a clear reduction in both the severity of chronic inflammation and the subsequent development of cancerous lesions.
Toward a New Standard of Care
The transition from laboratory discovery to clinical application is often a long one, but for IBD patients, there is cause for optimism. Because the research identifies a specific receptor interaction, it provides a clear blueprint for drug development.
Professor Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology and Rheumatology at Charité, emphasizes the complexity of these diseases and the importance of this new data. "Chronic inflammatory bowel diseases are highly complex and differ from person to person. That’s exactly what makes them so difficult to treat and predict treatment," she says. "Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The findings are already moving toward real-world application. A clinical trial is currently underway to test the safety and efficacy of an antibody designed to block the receptors for oncostatin M. If successful, this therapy could provide a lifeline for "non-responders"—those patients for whom current medical science previously had no effective answers.
By specifically disrupting the harmful synergy between IL-22 and OSM, researchers hope to "douse the fire" of inflammation before it causes irreversible tissue damage or oncogenic shifts. For the thousands of young people diagnosed each year, this research represents a significant step toward a future where chronic bowel disease is not just managed, but effectively silenced.
